london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Change in glycosylated haemoglobin in patients with centre involving diabetic macular edema treated with intravitreal ranibizumab

Session Details

Session Title: Vascular Diseases and Diabetic Retinopathy II

Session Date/Time: Friday 12/09/2014 | 11:00-13:00

Paper Time: 11:48

Venue: Boulevard C

First Author: : J.Kirk UK

Co Author(s): :    R. Healy   P. Scanlon   R. Johnston   Q. Mohamed     

Abstract Details


To evaluate the change in serum haemoglobin A1C in patients treated with intravitreal ranibizumab for centre-involving diabetic macular oedema with follow up of at least 6 months


Gloucestershire hospitals NHS foundation trust


All patients with centre-involving diabetic macular oedema treated with intravitreal ranibizumab with a minimum of 6 months follow up after first treatment were included. Data on baseline and sequential HbA1c values was retrospectively extracted from an electronic medical record (EMR) and pathology electronic records. Values at baseline and final follow up in patients with unilateral and bilateral involvement were analysed


189 eyes of 147 patients were included in the study. Mean age was 67 years. The male: female ratio was 1: 0.72. At baseline mean HbA1c for all patients was 65.2 mmol ± 18.4. Final HbA1c at last follow up was 65.0 mmol ± 19.3. Mean change in HbA1c was -0.2 mmol ± 17.4. The mean HbA1c in patients with bilateral involvement at baseline was 64.0mmol ± 16.0 and 63.1 mmol ± 17.5 at final follow up


In this real-world study the HbA1c values at baseline are worse than those reported in DRCRNet and RESTORE studies (57 mmols at baseline and 60 mmol at 1 year). There was no significant difference in HbA1c between patients with unilateral and both eye treatment. This study suggests that patients with CIDMO in real world practice have poorer glycemic control than those in pivotal studies. There is scope for improved multidisciplinary management in these high risk patients to improve glycaemic control and reduce morbidity and mortality

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy